Bayer vs Eli Lilly stock
Side by side in plain words: who keeps more of its sales, grows faster, costs less and owes less.
Eli Lilly is more profitable, grows faster, is cheaper for its profits and has less debt.
Side by side
| Bayer | Eli Lilly | |
|---|---|---|
| €55.5 billion | $1.29 trillion | |
| -7.9% | 31.7% | |
| −3.5% | +21.6% | |
| No profit yet | 62.3× | |
| 15.5 years | 1.1 years | |
| -1.0% | 34.8% | |
| 0.2% | 0.6% |
How we compare
Four contests with the same rules as each stock page: profit kept from sales (higher wins), yearly sales growth across the last reports, up to five years (higher wins), price per unit of yearly profit (lower P/E wins; a company without profit loses) and debt in years of earnings (lower wins). A winner is only named when both companies have the number.
More comparisons: Bayer vs Merck & · Bayer vs Roche · Bayer vs Johnson & Johnson · Eli Lilly vs Becton, Dickinson and · Eli Lilly vs Bristol-Myers Squibb · Eli Lilly vs Boston Scientific · Eli Lilly vs Cardinal Health